Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and commercializes human therapeutics. The company offers VIBATIV (telavancin), a bactericidal, once-daily injectable antibiotic to treat patients with infections due to staphylococcus aureus and other gram-positive bacteria. Its product candidates include TD-1792 that has completed Phase III clinical trials for the treatment of skin and soft tissues infections; Revefenacin (TD-4208), a long-acting muscarinic antagonist, which has completed Phase III clinical studies for chronic obstructive pulmonary disease (COPD); and Velusetrag (TD-5108), an oral and investigational medicine that has completed Phase IIb studies for gastrointestinal motility disorders. The company's product candidates also comprise TD-8954, a selective 5-HT4 receptor agonist for treating gastrointestinal motility disorders; TD-1473, a pan-Janus kinase inhibitor, which has completed Phase Ib clinical study for ulcerative colitis; TD-9855, an investigational norepinephrine and serotonin reuptake inhibitor that has completed Phase II study for neurogenic orthostatic hypotension; and TD-0714 and TD-1439 Neprilysin inhibitors, which have completed Phase I clinical studies for heart failure and chronic kidney disease. In addition, it focuses on various drug development programs, including the combination of fluticasone furoate, umeclidinium bromide, and vilanterol for the treatment of COPD and asthma; the inhaled bifunctional muscarinic antagonist-beta2 agonist program, as monotherapy; and in combination with other therapeutically active components, such as an inhaled corticosteroid. The company was incorporated in 2013 and is based in George Town, the Cayman Islands.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone650-808-6000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$15.39 million
Profitability
Miscellaneous
Employees340
OptionableOptionable
Theravance Biopharma (NASDAQ:TBPH) Frequently Asked Questions
What is Theravance Biopharma's stock symbol?
Theravance Biopharma trades on the NASDAQ under the ticker symbol "TBPH."
How were Theravance Biopharma's earnings last quarter?
Theravance Biopharma Inc (NASDAQ:TBPH) posted its quarterly earnings data on Tuesday, May, 8th. The biopharmaceutical company reported ($1.22) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($1.26) by $0.04. The biopharmaceutical company earned $8.32 million during the quarter, compared to the consensus estimate of $5.74 million. Theravance Biopharma had a negative net margin of 513.41% and a negative return on equity of 505.90%. View Theravance Biopharma's Earnings History.
When is Theravance Biopharma's next earnings date?
What price target have analysts set for TBPH?
4 analysts have issued 12-month target prices for Theravance Biopharma's stock. Their forecasts range from $38.00 to $55.00. On average, they expect Theravance Biopharma's share price to reach $47.00 in the next year. This suggests a possible upside of 70.5% from the stock's current price. View Analyst Price Targets for Theravance Biopharma.
What is the consensus analysts' recommendation for Theravance Biopharma?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Theravance Biopharma in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Theravance Biopharma.
What are Wall Street analysts saying about Theravance Biopharma stock?
Here are some recent quotes from research analysts about Theravance Biopharma stock:
- 1. According to Zacks Investment Research, "Theravance received a huge boost when the FDA approved Yupelri, the first once daily nebulized LAMA option for COPD, in November. The company plans to launch the drug by 2018 end. Meanwhile, the agreement to divest its only marketed drug, Vibativ, will enable Theravance to focus solely on the launch efforts of Yupelri. Moreover, its pipeline programs target highly competitive therapeutic areas. The company's collaboration agreements are a consistent source of funds. However, any agreement termination might be a huge setback for the company as was the case in the past. Shares of the company have outperformed the industry in 2018. Estimates looks stable ahead of the Q4 earnings release. Theravance has a positive record of earnings surprises in recent quarters." (2/11/2019)
- 2. Cantor Fitzgerald analysts commented, "We rate TBPH 12-month price target of $55. We believe the Street is underestimating the peak sales potential of its key programs (JAK Inhibitor, TD-9855, Revefenacin, among others) and preclinical assets. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $55. The Disclosure Section may be found on pages 3 – 4.Valuation We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $55." (1/28/2019)
- 3. Needham & Company LLC analysts commented, "Theravance provided a 2Q18 corporate update today and announced top-line results from the Phase 2 trial of Hypotension (NOH). An impact on both blood pressure and symptoms is apparent and mgmt announced plans to start a Phase 3 trial around YE18. Separately, Phase 2 trial of Colitis (UC) has also been completed. As a reminder, 80mg data had previously been disclosed. Mgmt noted that a dose-response across 20mg-80mg-270mg is evident and that full data will be presented later this yr. Initiation of larger and longer-term trials in UC and Crohns Disease are planned for 2H18. We continue to expect Yupelri (revefenacin) FDA approval in COPD by 11/13/18 PDUFA date. Reiterate BUY. Pipeline is diverse, but Theravance is making noteworthy progress w/ several programs." (8/1/2018)
Has Theravance Biopharma been receiving favorable news coverage?
Headlines about TBPH stock have trended somewhat positive on Sunday, InfoTrie reports. The research firm identifies negative and positive news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Theravance Biopharma earned a news sentiment score of 1.4 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 1.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next several days.
Who are some of Theravance Biopharma's key competitors?
Some companies that are related to Theravance Biopharma include Catalent (CTLT), Dr.Reddy's Laboratories (RDY), Amarin (AMRN), GALAPAGOS NV/S (GLPG), United Therapeutics (UTHR), Patheon (PTHN), Alkermes (ALKS), FibroGen (FGEN), Array Biopharma (ARRY), GW Pharmaceuticals PLC- (GWPH), TESARO (TSRO), Taro Pharmaceutical Industries (TARO), Amneal Pharmaceuticals (AMRX), Horizon Pharma (HZNP) and Agios Pharmaceuticals (AGIO).
Who are Theravance Biopharma's key executives?
Theravance Biopharma's management team includes the folowing people:
- Mr. Rick E. Winningham, Chairman & CEO (Age 58)
- Ms. Reneé D. Galá, Sr. VP, CFO & Treasurer (Age 46)
- Mr. Bradford J. Shafer, Exec. VP, Gen. Counsel & Sec. (Age 58)
- Dr. Shehnaaz Suliman M.D., M.Phil., M.B.A., Sr. VP of Corp. Devel. & Strategy (Age 46)
- Mr. Frank Pasqualone, Sr. VP & Global Head of Acute Care Bus. (Age 62)
Who are Theravance Biopharma's major shareholders?
Theravance Biopharma's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.97%), Northern Trust Corp (0.99%), Geode Capital Management LLC (0.90%), Chescapmanager LLC (0.75%), Candriam Luxembourg S.C.A. (0.50%) and Bank of New York Mellon Corp (0.38%). Company insiders that own Theravance Biopharma stock include Bradford J Shafer, Brett K Haumann, Burton G Malkiel, Frank Pasqualone, Henrietta Fore, Philip D Worboys, Renee D Gala and Rick E Winningham. View Institutional Ownership Trends for Theravance Biopharma.
Which institutional investors are selling Theravance Biopharma stock?
TBPH stock was sold by a variety of institutional investors in the last quarter, including Barclays PLC, Ibex Investors LLC, Virtus ETF Advisers LLC, Principal Financial Group Inc., California Public Employees Retirement System, NJ State Employees Deferred Compensation Plan, New York State Common Retirement Fund and Old West Investment Management LLC. Company insiders that have sold Theravance Biopharma company stock in the last year include Bradford J Shafer, Philip D Worboys and Renee D Gala. View Insider Buying and Selling for Theravance Biopharma.
Which institutional investors are buying Theravance Biopharma stock?
TBPH stock was bought by a variety of institutional investors in the last quarter, including First Trust Advisors LP, Chicago Equity Partners LLC, Geode Capital Management LLC, BlackRock Inc., Candriam Luxembourg S.C.A., D. E. Shaw & Co. Inc., Rhumbline Advisers and Bank of America Corp DE. Company insiders that have bought Theravance Biopharma stock in the last two years include Burton G Malkiel, Frank Pasqualone, Henrietta Fore and Rick E Winningham. View Insider Buying and Selling for Theravance Biopharma.
How do I buy shares of Theravance Biopharma?
Shares of TBPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Theravance Biopharma's stock price today?
One share of TBPH stock can currently be purchased for approximately $27.56.
How big of a company is Theravance Biopharma?
Theravance Biopharma has a market capitalization of $1.53 billion and generates $15.39 million in revenue each year. The biopharmaceutical company earns $-285,400,000.00 in net income (profit) each year or ($5.45) on an earnings per share basis. Theravance Biopharma employs 340 workers across the globe.
What is Theravance Biopharma's official website?
How can I contact Theravance Biopharma?
Theravance Biopharma's mailing address is UGLAND HOUSE SOUTH CHURCH STREET, GEORGE TOWN E9, KY1-1104. The biopharmaceutical company can be reached via phone at 650-808-6000 or via email at [email protected]
MarketBeat Community Rating for Theravance Biopharma (NASDAQ TBPH)
MarketBeat's community ratings are surveys of what our community members think about Theravance Biopharma and other stocks. Vote "Outperform" if you believe TBPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TBPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
